| Identification | Back Directory | [Name]
JNJ-38877605 | [CAS]
943540-74-7 | [Synonyms]
OMO-1)
JNJ-38877618
JNJ-38877618
(OMO1
6-[Difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline
6-(difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline
Quinoline, 6-[difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]- | [Molecular Formula]
C20H12F2N6 | [MDL Number]
MFCD31657377 | [MOL File]
943540-74-7.mol | [Molecular Weight]
374.35 |
| Hazard Information | Back Directory | [Uses]
JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. | [Biological Activity]
JNJ-38877618 (OMO-1) is a potent, highly selective, and orally bioavailable Met (c-Met) kinase inhibitor with a Kd of 1.4 nM. Its IC50 values for wild-type Met (c-Met) and mutant Met (c-Met) (M1268T) were 2 nM and 3 nM, respectively. | [in vivo]
In vivo, JNJ-38877618(OMO-1) completely inhibited tumor growth in 3 tumor models: SNU5 MET amp gastric cancer model, U87-MG HGF autocrine glioblastoma model, and exon 14 skipping deletion mutation Hs746T gastric cancer model of MET gene. Administration of OMO-1 in combination with other drugs is well tolerated and can improve and enhance the effect of EGFR-targeted therapy. Although single-agent OMO-1 has no effect on NSCLC HCC827 EGFR, its combination with erlotinib can delay tumor recurrence. | [target]
| Target | Value | Met
(Cell-free assay) | 2 nM | MET (M1268T)
(Cell-free assay) | 3 nM | < /table>[storage]
Store at -20°C | [References]
[1] Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquire |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|
|
Tags:943540-74-7
Related Product Information
|
|
|
|